- Home
- BXC vs BCAX Comparison
BXC vs BCAX Comparison
Compare BXC & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- BCAX
- Stock Information
- Founded
- BXC 2004
- BCAX 2018
- Country
- BXC United States
- BCAX United States
- Employees
- BXC N/A
- BCAX N/A
- Industry
- BXC Wholesale Distributors
- BCAX
- Sector
- BXC Consumer Discretionary
- BCAX
- Exchange
- BXC Nasdaq
- BCAX NYSE
- Market Cap
- BXC 663.8M
- BCAX 670.9M
- IPO Year
- BXC 2004
- BCAX 2024
- Fundamental
- Price
- BXC $76.61
- BCAX $13.40
- Analyst Decision
- BXC Strong Buy
- BCAX Strong Buy
- Analyst Count
- BXC 5
- BCAX 6
- Target Price
- BXC $126.20
- BCAX $34.20
- AVG Volume (30 Days)
- BXC 88.8K
- BCAX 615.0K
- Earning Date
- BXC 04-29-2025
- BCAX 03-27-2025
- Dividend Yield
- BXC N/A
- BCAX N/A
- EPS Growth
- BXC 14.84
- BCAX N/A
- EPS
- BXC 6.19
- BCAX N/A
- Revenue
- BXC $2,952,532,000.00
- BCAX N/A
- Revenue This Year
- BXC $4.52
- BCAX N/A
- Revenue Next Year
- BXC $5.77
- BCAX N/A
- P/E Ratio
- BXC $12.38
- BCAX N/A
- Revenue Growth
- BXC N/A
- BCAX N/A
- 52 Week Low
- BXC $73.01
- BCAX $11.10
- 52 Week High
- BXC $134.79
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- BXC 36.10
- BCAX N/A
- Support Level
- BXC $79.74
- BCAX N/A
- Resistance Level
- BXC $84.33
- BCAX N/A
- Average True Range (ATR)
- BXC 2.68
- BCAX 0.00
- MACD
- BXC 0.76
- BCAX 0.00
- Stochastic Oscillator
- BXC 9.81
- BCAX 0.00
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.